Barchetta I, Cimini F A, Bloise D, Cavallo M G
Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Diabetes Unit, San Giuseppe Hospital of Marino, Rome, Italy.
Acta Diabetol. 2016 Oct;53(5):839-44. doi: 10.1007/s00592-016-0882-9. Epub 2016 Jul 5.
Dipeptidyl peptidase-4 inhibitors (DPP4-Is) represent a promising class of agents for type 2 diabetes treatment. Experimental models and clinical studies have reported positive effects of DPP4-Is on bone; however, how DPP4-Is positively impact bone homeostasis in humans remains an unanswered question. Aim of this study investigated the relationship between treatment with DPP4-Is and vitamin D balance in patients with type 2 diabetes.
This is a cross-sectional study. A total of 295 consecutive individuals with type 2 diabetes referring to our diabetes outpatient clinics were enrolled; among them, 53 % were in treatment with DPP4-Is. Metabolic profile and routine biochemistry were assessed by standard methods; serum 25(OH) vitamin D levels [25(OH)D] were measured by colorimetric method (LAISON, DiaSorin).
DPP4-Is-treated participants had significantly higher serum 25(OH)D levels then those undertaking other antidiabetic therapies (18.4 ± 10.7 vs. 14.9 ± 8.6 ng/ml, p = 0.004); this association persisted after adjusting for all major confounders. Increased 25(OH)D concentrations also correlated with the duration of DPP4-Is treatment and with a stronger DPP4 inhibitory activity.
DPP4-Is treatment is associated with improved vitamin D balance in people with type 2 diabetes; our findings suggest that vitamin D may underlie the link between DPP4-Is and bone metabolism.
二肽基肽酶 -4 抑制剂（DPP4 -Is）是一类有前景的 2 型糖尿病治疗药物。实验模型和临床研究已报道 DPP4 -Is 对骨骼有积极作用；然而，DPP4 -Is 如何在人体中积极影响骨稳态仍是一个未解决的问题。本研究旨在调查 2 型糖尿病患者中 DPP4 -Is 治疗与维生素 D 平衡之间的关系。
这是一项横断面研究。共纳入 295 例连续到我们糖尿病门诊就诊的 2 型糖尿病患者；其中，53%正在接受 DPP4 -Is 治疗。通过标准方法评估代谢谱和常规生化指标；采用比色法（LAISON，DiaSorin）测定血清 25(OH)维生素 D 水平[25(OH)D]。
接受 DPP4 -Is 治疗的参与者血清 25(OH)D 水平显著高于接受其他抗糖尿病治疗的参与者（18.4 ± 10.7 与 14.9 ± 8.6 ng/ml，p = 0.004）；在调整所有主要混杂因素后，这种关联仍然存在。25(OH)D 浓度的升高还与 DPP4 -Is 治疗的持续时间以及更强的 DPP4 抑制活性相关。
DPP4 -Is 治疗与
